Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.
Thomas Martin, MD, University of California San Francisco
Advertisement
Articles by Thomas Martin, MD, University of California San Francisco
Advertisement
Latest Updated Articles
Targeted Treatment Options in Multiple MyelomaPublished: August 10th 2020 | Updated:
The Future of Multiple MyelomaPublished: August 10th 2020 | Updated:
A Look at the ENDURANCE TrialPublished: August 10th 2020 | Updated:
Maintenance Therapy in Multiple MyelomaPublished: August 10th 2020 | Updated:
Treatment Options in Relapsed/Refractory Multiple MyelomaPublished: August 10th 2020 | Updated:
Trials in Relapsed/Refractory Multiple MyelomaPublished: August 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5